Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.67 |
| ▸ | CNR2 | P34972 | 15/20 | 0.53 |
| ▸ | CNR1 | P21554 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559134 | 0.90 | CNR2 (0.59) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5558009 | 0.88 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5559131 | 0.86 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5553031 | 0.83 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL5469053 | 0.83 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL6224705 | 0.83 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DCNR2 | |
| SCHEMBL6220881 | 0.83 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL6223861 | 0.82 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5559108 | 0.82 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5557937 | 0.82 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | claimed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | claimed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.